Thus, we have shown that TRIM25 negatively regulates the stability of BRD7 protein through the ubiquitin-proteasome pathway, and confirmed the direct binding domains of TRIM25 and BRD7, which provide the molecular basis for further development of targeted therapy for the treatment of breast cancer. Here, BRD7 is linked to breast carcinoma.